

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
27 April 2023 (27.04.2023)



(10) International Publication Number
WO 2023/066283 A1

(51) International Patent Classification:

C07D 239/80 (2006.01) C07D 519/00 (2006.01)
C07D 403/02 (2006.01) A61K 31/519 (2006.01)
C07D 403/14 (2006.01) A61P 35/00 (2006.01)
C07D 487/04 (2006.01)

(21) International Application Number:

PCT/CN2022/126096

(22) International Filing Date:

19 October 2022 (19.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2021/125035
20 October 2021 (20.10.2021) CN
PCT/CN2022/116510
01 September 2022 (01.09.2022) CN

(71) Applicant: **INSILICO MEDICINE IP LIMITED**
[CN/CN]; 26th Floor, Three Exchange Square, 8 Connaught
Place Central, Hong Kong (CN).

(72) Inventors: **CHEN, Chiachun**; Suite 902, Tower E, Chang-
tai Plaza, 2889 Jinke Road, Pudong New District, Shang-
hai 201203 (CN). **DING, Xiao**; Suite 902, Tower E, Chang-
tai Plaza, 2889 Jinke Road, Pudong New District, Shanghai
201203 (CN). **LIU, Xiaosong**; Suite 902, Tower E, Chang-
tai Plaza, 2889 Jinke Road, Pudong New District, Shang-
hai 201203 (CN). **MENG, Qingyuan**; Suite 902, Tower
E, Changtai Plaza, 2889 Jinke Road, Pudong New District,
Shanghai 201203 (CN). **REN, Feng**; Suite 902, Tower E,
Changtai Plaza, 2889 Jinke Road, Pudong New District,
Shanghai 201203 (CN). **WANG, Hailong**; Suite 902, Tow-
er E, Changtai Plaza, 2889 Jinke Road, Pudong New Dis-
trict, Shanghai 201203 (CN).

(74) Agent: **AFD CHINA INTELLECTUAL PROPERTY
LAW OFFICE**; Tower B, 21st Fl., Suite 2108, 38 Xueqing
Road, Haidian, Beijing 100083 (CN).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

WO 2023/066283 A1

(54) Title: METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITORS AND USES THEREOF

(57) Abstract: Described herein are MAT2A inhibitors and pharmaceutical compositions comprising said inhibitors. The subject com-
pounds and compositions are useful for the treatment of a disease or disorder associated with MAT2A.